Can Patient-Centered Prescription Labels Increase Medication Adherence?
Drug Topics
FEBRUARY 9, 2023
Researchers evaluated how changes in USP labeling standards have affected adherence across multiple classes of drugs.
Thu.Feb 09, 2023
186 
Opinion: The fungal crisis is here and desperately needs addressing
STAT
FEBRUARY 9, 2023
Fungus-caused infections — real ones, not the ones sparking the zombie apocalypse on the popular show “The Last of Us” — pose a growing threat in the United States and around the world. Mississippi has become the latest state to report residents infected with Candida auris, a highly contagious fungus that thrives in hospitals and nursing homes.
Join 18,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
The Variants of COVID-19
Drug Topics
FEBRUARY 9, 2023
XBB, a less severe but more contagious strain of COVID-19, has taken over as the dominant Omicron strain.
Study suggests DNA sequencing could reduce infant deaths, often caused by genetic disease
STAT
FEBRUARY 9, 2023
Researchers who believe genomics can transform human health love to recount success stories. They’ll tell you about the 3-month-old boy whose heart was failing until researchers pinpointed what was ailing him. Or the baby girl who could have had a life-threatening reaction to anesthesia had researchers not sequenced her DNA ahead of time. But a new study focuses on a much more somber set of stories: those of infants who died with genetic diseases and who in some cases could have been trea
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Assessing Biologic Medications for Effective Management of Severe Asthma in Adults
Drug Topics
FEBRUARY 9, 2023
The use of biomarker profiles to guide asthma treatment decisions have not been well-studied.
NCPA endorses reintroduction of Senate FTC/PBM bills
Drug Store News
FEBRUARY 9, 2023
NCPA issued gratitude to Sens. Cantwell and Grassley for their efforts to "pull back the curtain on PBMs and push for FTC review of anticompetitive PBM practices.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Disruptive Factors Shape RA Landscape
Pharmaceutical Commerce
FEBRUARY 9, 2023
As the range of treatment options for rheumatoid arthritis (RA) continues to grow and biosimilars are poised to enter the arena, the need for expert strategies to improve therapy selection and address the access, affordability, and adherence challenges patients face is coming into sharper focus.
The 2023 Dermatology Drug Pipeline
Drug Topics
FEBRUARY 9, 2023
This year will be an exciting one for dermatologic therapy and pharmacology as treatments continue to evolve.
COVID Benefits Are Changing
DiversifyRx
FEBRUARY 9, 2023
While COVID will be sticking around, many of the patient financial COVID benefits will be going away soon. The COVID-19 pandemic has brought about numerous changes in the way we live and access healthcare. The emergency COVID measures that are currently active now have an expiration date: May 11, 2023. This means that in just a matter of months, the benefits we’ve come to rely on may no longer be available.
In large study, a single antibiotic dose slashed rate of sepsis in childbirth
STAT
FEBRUARY 9, 2023
An inexpensive and easy-to-deliver intervention — a single dose of the antibiotic azithromycin — could sharply reduce the number of pregnant people in low- and middle-income countries who develop the life-threatening condition sepsis in childbirth, a study published Thursday reported. The results of an international trial , published in the New England Journal of Medicine, showed that administration of the antibiotic during labor cut the risk of the mother developing sepsis by abou
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Taking Steps to Right the Wrongs: The Impact of Racial Bias in Healthcare and Medicine
PharmExec
FEBRUARY 9, 2023
Health disparities brought on by racial bias remain quite prevalent in areas such as drug access, use of diagnostics, and representation in clinical trials, but society-jarring events in recent years have sparked renewed efforts by industry to tackle these issues with tangible and hopeful gains.
Dapagliflozin approved in EU for heart failure across full ejection fraction spectrum
Hospital Pharmacy Europe
FEBRUARY 9, 2023
The sodium-glucose co-transporter 2 inhibitor dapagliflozin has received EU approval for use in symptomatic chronic heart failure Although used for the management of type 2 diabetes, dapagliflozin (brand name Forxiga) has now been approved in the EU for patients with heart failure across the full spectrum of ejection fractions according to a press release by the manufacturer, AstraZeneca.
STAT+: Cigarette, vape maker Reynolds American calls on the FDA to pull Puff Bar, Elf Bar, and other disposables off store shelves
STAT
FEBRUARY 9, 2023
WASHINGTON — Cigarette giant Reynolds American is calling on the Food and Drug Administration to crack down on manufacturers of disposable e-cigarettes, like Puff Bar and Elf Bar, which are increasingly being used by young people. The company, which also makes Vuse e-cigarettes, submitted a formal “citizen petition” to the FDA earlier this week calling on the agency to adopt an enforcement policy specifically targeted at disposable competitors to its products.
Teva Pharmaceutical reports 5% fall in Q4 2022 revenue
Pharmaceutical Technology
FEBRUARY 9, 2023
Teva Pharmaceutical Industries has reported $3.9bn revenue in the fourth quarter (Q4) of 2022, representing a 5% decline in US dollars or a 1% increase in local currency terms, from $4.1bn in the same quarter of the previous year. During the quarter, higher revenues from Anda, generic products in the Europe segment, AJOVY and AUSTEDO were partially offset by fewer revenues from COPAXONE, generic products and certain respiratory products in the North America segment.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
How to help patients taking controlled medications
The Checkup by Singlecare
FEBRUARY 9, 2023
As a pharmacist, you are likely well aware of what the Drug Enforcement Agency (DEA) calls your “corresponding responsibility” in section Title 21 of the Code of Federal Regulations. The law states that a pharmacist must only fill a prescription for a controlled substance when it is issued for a legit medical reason by a legitimate practitioner acting within the usual scope of their professional practice.
ReviR Therapeutics partners with Asieris to develop new oncology therapies
Pharmaceutical Technology
FEBRUARY 9, 2023
ReviR Therapeutics has signed a research collaboration and option-to-license agreement with Asieris Pharmaceuticals to discover new oncology therapeutics. The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies.
STAT+: Engineered virus shows promise against aggressive form of breast cancer
STAT
FEBRUARY 9, 2023
When breast oncologists see new patients, one of their hopes is that the patient doesn’t have triple-negative breast cancer. The subtype is considered particularly dangerous, as it tends to grow and spread more aggressively than other types, and it has fewer effective treatment options. But a small new study suggests that help might come from an engineered virus.
Bausch + Lomb kicks off social media campaign for AMD awareness
Drug Store News
FEBRUARY 9, 2023
The campaign features personal stories and images from Bausch + Lomb SightMatters community members during age-related macular degeneration month.
New hybrid provider Enabled Healthcare launches in Washington with a focus on older adults with chronic conditions
Fierce Healthcare
FEBRUARY 9, 2023
New hybrid provider Enabled Healthcare launches in Washington with a focus on older adults with chronic conditions agliadkovskaya Thu, 02/09/2023 - 13:59
STAT+: Senate panel passes drug patent reforms, but not without dissent
STAT
FEBRUARY 9, 2023
WASHINGTON — The Senate Judiciary Committee on Thursday passed legislation to prevent drug companies from gaming the patent system to delay competition from cheaper generics, but members in both parties said they still have concerns about the reforms. The measure also seeks to curb a practice of filing dozens of patents on drugs to forestall competition from generic drugs and biosimilars by restricting the number of patents that patent holders can contest.
Target adds new brands to health, beauty aisles
Drug Store News
FEBRUARY 9, 2023
A majority of the new items are under $10, and the retailer is putting a spotlight on clean products, as well as Black-owned and inclusive brands.
STAT+: How the CPAP crisis has paved the way for Philips’ biggest rivals to rake in profits
STAT
FEBRUARY 9, 2023
The Philips respiratory machine recall is a no-win situation for patients and doctors. But for the medical device giant’s longtime rivals and new competitors, business is looking up. “We think it will be difficult for Philips to regain all the share that they had,” said Margaret Kaczor, an analyst with William Blair who follows ResMed among other companies.
Docs likely to be 'cautious' when prescribing GSK's first-in-class anemia drug Jesduvroq, survey finds
Fierce Pharma
FEBRUARY 9, 2023
Docs likely to be 'cautious' when prescribing GSK's first-in-class anemia drug Jesduvroq, survey finds fkansteiner Thu, 02/09/2023 - 14:18
Ardell Beauty’s Active Lash caters to those on-the-go
Drug Store News
FEBRUARY 9, 2023
The Active Lash line was designed to ensure that consumers can wear the brand's lashes when working out or doing intense activities.
Eli Lilly's employment decisions under fire once again as sales rep lodges age discrimination claim
Fierce Pharma
FEBRUARY 9, 2023
Eli Lilly's employment decisions under fire once again as sales rep lodges age discrimination claim zbecker Thu, 02/09/2023 - 14:45
HHS releases new guidance implementing key Medicare drug rebate program
Fierce Healthcare
FEBRUARY 9, 2023
HHS releases new guidance implementing key Medicare drug rebate program rking Thu, 02/09/2023 - 16:01
Native helps define curls with Curl Care collection
Drug Store News
FEBRUARY 9, 2023
Native’s Curl Care line is formulated to enhance natural waves and minimize frizz without weighing down hair, the company said.
Could oral difelikefalin be first FDA-approved drug for notalgia paresthetica?
European Pharmaceutical Review
FEBRUARY 9, 2023
Oral difelikefalin could potentially relieve the moderate-to-severe itching associated with notalgia paresthetica, according to a study published in the New England Journal of Medicine. Notalgia paresthetica is a nerve disorder characterised by a persistent itch in the upper back. To date, there are no US Food and Drug Administration (FDA)-approved treatments specifically targeting this disorder.
AbbVie 'comfortable' after Humira biosim launch, as CEO forecasts 'stable' sales for star med into next year
Fierce Pharma
FEBRUARY 9, 2023
AbbVie 'comfortable' after Humira biosim launch, as CEO forecasts 'stable' sales for star med into next year fkansteiner Thu, 02/09/2023 - 11:01
Listen: The return of bird flu and the effects of pandemic fatigue
STAT
FEBRUARY 9, 2023
Just how alarming is bird flu? And did we learn enough from Covid-19 to be sensible about it? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Helen Branswell, STAT’s senior writer covering infectious disease, joins us to explain the sudden resurgence of a bird flu virus called H5N1 and why experts are watching the situation closely.
Galapagos' Jyseleca flops phase 3 Crohn's study, dealing another blow to troubled JAK inhibitor
Fierce Pharma
FEBRUARY 9, 2023
Galapagos' Jyseleca flops phase 3 Crohn's study, dealing another blow to troubled JAK inhibitor zbecker Thu, 02/09/2023 - 09:56
Take AstraZeneca’s warning seriously. The UK is missing out in life sciences
The Guardian - Pharmaceutical Industry
FEBRUARY 9, 2023
Big pharma has choices about where to make new investments and, increasingly it seems, it is not choosing Britain Another day, another warning from the pharmaceutical sector that ministers’ ambitions to make the UK “a life sciences superpower” are in danger of falling flat. The comments from Sir Pascal Soriot, chief executive of AstraZeneca, were different in one important respect, however.
Evernorth study: Risk of suicide on the rise among youth
Fierce Healthcare
FEBRUARY 9, 2023
Evernorth study: Risk of suicide on the rise among youth pminemyer Thu, 02/09/2023 - 13:39
Regeneron wins another FDA nod for powerhouse Eylea despite trial flops
Fierce Pharma
FEBRUARY 9, 2023
Regeneron wins another FDA nod for powerhouse Eylea despite trial flops kdunleavy Thu, 02/09/2023 - 10:30
Let's personalize your content